PHARMACEUTICAL EXECUTIVE NEWSLETTER

In this ISSUE

Are You Winning or Losing in Pharma 2.0?

ISPOR Task Force Grapples with Value Questions

BergstrÖm in the Crossfire

Opinion

Real-World Evidence: From Volume to Value

Pharm Exec convenes an expert Roundtable to discuss one of the hottest topics in big data today—how to make that data relevant to payers, regulators and the patient through reliance on real-world evidence in driving better health outcomes.
... /Read more/

Read this Front & Center article to see how your Hub can be a Secret Weapon to improve Outcomes.

Learn more

Pricing & Reimbursement

Value Assessment of Drugs Here to Stay

Despite notable deficiencies in the frameworks for assessing the value of prescription drugs, these initiatives are expected to have a major impact on drug utilization and reimbursement.
... /Read more/

Investment

'Huge Sellers' Herald Changes in Japan Drug Pricing

The latest price rules revision is both radical and rare by the government's usual exhaustive standards. What do they mean for pharma players in the world's third-largest market?
... /Read more/

Regulatory Affairs

Lost Leaders? EU Health and Brexit

The UK's vote to leave the EU was the hot topic — and a source of exasperation — at last week's annual European Health Forum Gastein.
... /Read more/

Calendar

/ Outcomes-Based Contracting Summit /

/ NORD 2016 Rare Diseases & Orphan Products Breakthrough Summit /

/ RIM 2016 - Regulatory Information Management /

/ Electronic Benefit Verification & Prior Authorization Summit /

Regualtory Affairs

Major Changes Ahead for Drug User Fees

PDUFA VI to enhance FDA staffing, revise fees and expand evidence for drug development.
... /Read more/

update my profile / advertise with us / print & digital subscribe / visit pharmexec.com